| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, and Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115
Malignant pleural mesothelioma (MPM) is a rare malignancy with no known curative modality. Approximately 70% of MPMs have high levels of expression of the epidermal growth factor receptor (EGFR), and a subset of cell lines derived from MPM patients express both EGFR and transforming growth factor 
, suggesting an autocrine role for EGFR in MPM. We have determined the effects of EGFR inhibition in MPM cell lines in vitro, using four MPM cell lines derived from previously untreated patients with epithelial (H2461 and H2591), sarcomatoid (H2373), and biphasic (MSTO-211H) MPM. All four cell lines expressed EGFR at levels comparable with the non-small cell lung carcinoma (NSCLC) cell line A549, as shown by Western blot analysis. ZD1839 significantly inhibited epidermal growth factor-dependent cell signaling including phosphorylation of AKT and extracellular signal-regulated kinases 1 and 2 in all MPM cell lines. Furthermore, treatment with ZD1839 led to a significant dose-dependent reduction of colony formation (41–89% at 10 µM) when MPM cells were grown in soft agarose. MSTO-211H, H2461, and H2373 were more sensitive to the growth-inhibitory effects of ZD1839 than was the NSCLC cell line A549, whereas H2591 had similar sensitivity to A549. This variability in growth-inhibitory effects is not related to the amount of EGFR present on MPM cells or to the degree of inhibition of EGFR phosphorylation by ZD1839. We show that H2373 MPM cells, which show 89% growth inhibition at 10 µM ZD1839, undergo a dose-dependent arrest at the G1-S phase of the cell cycle and a corresponding increase in p27 levels. However, H2591 cell lines, which show 41% growth inhibition at 10 µM ZD1839, undergo no significant cell cycle changes or changes in p27 levels. Our findings demonstrate that in vitro, ZD1839 is as effective or more effective against MPM cell lines as it is against the NSCLC cell line A549 and suggest that ZD1839 may be an effective therapeutic option for patients with MPM.
This article has been cited by other articles:
|
|
 |
|
  A. Shukla, M. W. Bosenberg, M. B. MacPherson, K. J. Butnor, N. H. Heintz, H. I. Pass, M. Carbone, J. R. Testa, and B. T. Mossman Activated cAMP Response Element Binding Protein Is Overexpressed in Human Mesotheliomas and Inhibits Apoptosis Am. J. Pathol., November 1, 2009; 175(5): 2197 - 2206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Catalano, R. Lazzarini, S. Di Nuzzo, S. Orciari, and A. Procopio The Plexin-A1 Receptor Activates Vascular Endothelial Growth Factor-Receptor 2 and Nuclear Factor-{kappa}B to Mediate Survival and Anchorage-Independent Growth of Malignant Mesothelioma Cells Cancer Res., February 15, 2009; 69(4): 1485 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Garland, C. Rankin, D. R. Gandara, S. E. Rivkin, K. M. Scott, R. B. Nagle, A. J.P. Klein-Szanto, J. R. Testa, D. A. Altomare, and E. C. Borden Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study J. Clin. Oncol., June 10, 2007; 25(17): 2406 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Koyama, Y. Matsuzaki, S. Yogosawa, T. Hitomi, M. Kawanaka, and T. Sakai ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway Mol. Cancer Ther., May 1, 2007; 6(5): 1579 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Melo, M. W. Gerbase, J. Curran, and J.-C. Pache Phosphorylated Extracellular Signal-regulated Kinases Are Significantly Increased in Malignant Mesothelioma J. Histochem. Cytochem., August 1, 2006; 54(8): 855 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mukohara, G. Civiello, I. J. Davis, M. L. Taffaro, J. Christensen, D. E. Fisher, B. E. Johnson, and P. A. Janne Inhibition of the Met Receptor in Mesothelioma Clin. Cancer Res., November 15, 2005; 11(22): 8122 - 8130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Rascoe, X. Cao, J. C. Daniel, S. D. Miller, and W. R. Smythe Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 393 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Xia, S. R. Kumar, R. Masood, M. Koss, C. Templeman, D. Quinn, S. Zhu, R. Reddy, V. Krasnoperov, and P. S. Gill Up-Regulation of EphB4 in Mesothelioma and Its Biological Significance Clin. Cancer Res., June 15, 2005; 11(12): 4305 - 4315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hirata, F. Hosoi, M. Miyagawa, S.-i. Ueda, S. Naito, T. Fujii, M. Kuwano, and M. Ono HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells Cancer Res., May 15, 2005; 65(10): 4253 - 4260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Cole Jr, A. M. Alleva, R. M. Reddy, J. B. Maxhimer, J. Zuo, D. S. Schrump, and D. M. Nguyen The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1010 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Govindan, R. A. Kratzke, J. E. Herndon II, G. A. Niehans, R. Vollmer, D. Watson, M. R. Green, H. L. Kindler, and on behalf of the Cancer and Leukemia Group B Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B Clin. Cancer Res., March 15, 2005; 11(6): 2300 - 2304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cesario, A. Catassi, L. Festi, A. Imperatori, A. Pericelli, D. Galetta, S. Margaritora, V. Porziella, V. Cardaci, P. Granone, et al. Farnesyltransferase Inhibitors and Human Malignant Pleural Mesothelioma: A First-Step Comparative Translational Study Clin. Cancer Res., March 1, 2005; 11(5): 2026 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tracy, T. Mukohara, M. Hansen, M. Meyerson, B. E. Johnson, and P. A. Janne Gefitinib Induces Apoptosis in the EGFRL858R Non-Small-Cell Lung Cancer Cell Line H3255 Cancer Res., October 15, 2004; 64(20): 7241 - 7244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nguyen, W. D. Schrump, G. A. Chen, W. Tsai, P. Nguyen, J. B. Trepel, and D. S. Schrump Abrogation of p21 Expression by Flavopiridol Enhances Depsipeptide-Mediated Apoptosis in Malignant Pleural Mesothelioma Cells Clin. Cancer Res., March 1, 2004; 10(5): 1813 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Catania, G. Colombo, A. Carlin, L. Garofalo, S. Gatti, R. Buffa, N. Carboni, L. Rosso, L. Santambrogio, L. Cantalamessa, et al. Autocrine inhibitory influences of {alpha}-melanocyte-stimulating hormone in malignant pleural mesothelioma J. Leukoc. Biol., February 1, 2004; 75(2): 253 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lu, C. Speers, Y. Zhang, X. Xu, J. Hill, E. Steinbis, J. Celestino, Q. Shen, H. Kim, S. Hilsenbeck, et al. Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors J Natl Cancer Inst, December 17, 2003; 95(24): 1825 - 1833. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
